Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate (Q38049170)

27 August 2017

Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate (English)

1 reference

27 August 2017

0 references

Mario Cozzolino

1

0 references

author name string

Elena Bruschetta

2

1 reference

27 August 2017

Daniele Cusi

3

1 reference

27 August 2017

Emanuele Montanari

4

1 reference

27 August 2017

Maria Enrica Giovenzana

5

1 reference

27 August 2017

Andrea Galassi

6

1 reference

27 August 2017

language of work or name

English

0 references

publication date

4 October 2012

1 reference

Expert Opinion on Pharmacotherapy

27 August 2017

1 reference

27 August 2017

13

1 reference

27 August 2017

16

1 reference

27 August 2017

2337-2353

1 reference

Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Regulation of phosphorus homeostasis by the type iia na/phosphate cotransporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

"Phosphatonins" and the regulation of phosphorus homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Endocrine functions of bone in mineral metabolism regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Klotho: an antiaging protein involved in mineral and vitamin D metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Phosphate elimination in modalities of hemodialysis and peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

A kinetic model of inorganic phosphorus mass balance in hemodialysis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Phosphorus binders and survival on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Nutrition and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Use of a renal-specific oral supplement by haemodialysis patients with low protein intake does not increase the need for phosphate binders and may prevent a decline in nutritional status and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Pathogenesis of vascular calcification in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Phosphate regulation of vascular smooth muscle cell calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Association of serum phosphate levels with aortic valve sclerosis and annular calcification: the cardiovascular health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Arterial calcifications and bone histomorphometry in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Pulse wave velocity is inversely related to vertebral bone density in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Relation between serum phosphate level and cardiovascular event rate in people with coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Forging forward with 10 burning questions on FGF23 in kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

What would we like to know, and what do we not know about fibroblast growth factor 23?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Does FGF23 toxicity influence the outcome of chronic kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

FGF23 induces left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Effects of phosphate binders in moderate CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Binder blinders-niacin of omission?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

The phosphate binder equivalent dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Lanthanum carbonate--a first line phosphate binder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Effects of treatment of renal osteodystrophy on bone histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Lanthanum activates calcium-sensing receptor and enhances sensitivity to calcium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Lanthanum acetate inhibits vascular calcification induced by vitamin D3 plus nicotine in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Relations of Serum Phosphorus and Calcium Levels to the Incidence of Cardiovascular Disease in the Community

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Mortality in kidney disease patients treated with phosphate binders: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

Phosphate binders in CKD: bad news or good news?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.730520

10.1517/14656566.2012.730520

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference